VEGFA and neoplasm: AZD5363 treatment significantly reduced the levels of human VEGF in tumours compared with those found in tumours from vehicle‐treated mice (846.7 ± 158.3 pg/ml vs. 1,435 ± 113.0 pg/ml, respectively; P = 0.01; Fig 5C).